p.4 抽出テキスト

.......................................................................................................................................................................... Table 9 Treatment of right ventricular failure in acute high-risk pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565 Table 10 Thrombolytic regimens, doses, and contra indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567 Table 11 Categorization of risk factors for venous thromboembolism based on the risk of recurrence over the long-term . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575 Table 12 Estimated radiation absorbed in procedures used for diagnosing pulmonary embolism (based on various references) . . . . . 581 Table 13 Risk factors and predisposing conditions for Chronic thromboembolic pulmonary hypertension . . . . . . . . . . . . . . . . . . . . . . . . . 584

List of figures

Figure 1 Trends in annual incidence rates and case fatality rates of pulmonary embolism around the world, based on data retrieved from various references . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 551 Figure 2 Key factors contributing to haemodynamic collapse and death in acute pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . 553 Figure 3 Graphic representation of transthoracic echocardiographic parameters in the assessment of right ventricular pressure overload . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 558 Figure 4 Diagnostic algorithm for patients with suspected high-risk pulmonary embolism, presenting with haemodynamic instability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570 Figure 5 Diagnostic algorithm for patients with suspected pulmonary embolism without haemodynamic instability . . . . . . . . . . . . 571 Figure 6 Risk-adjusted management strategy for acute pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 573 Figure 7 Diagnostic workup for suspected pulmonary embolism during pregnancy and up to 6 weeks post-partum . . . . . . . . 580 Figure 8 Follow-up strategy and diagnostic workup for long-term sequelae of pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . 586

Abbreviations and acronyms

AcT Right ventricular outflow Doppler acceleration time AFE Amniotic fluid embolism ALT Alanine aminotransferase AMPLIFY Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy ASPIRE Aspirin to Prevent Recurrent Venous Thromboembolism trial AV Arteriovenous b.i.d Bis in die (twice a day) BNP B-type natriuretic peptide BP Blood pressure BPA Balloon pulmonary angioplasty b.p.m Beats per minute CI Confidence interval CO Cardiac output CPET Cardiopulmonary exercise testing CPG Committee for Practice Guidelines CrCl Creatinine clearance CRNM Clinically relevant non-major (bleeding) CT Computed tomogram/tomographic/tomography CTED Chronic thromboembolic disease CTEPH Chronic thromboembolic pulmonary hypertension CTPA Computed tomography pulmonary angiography/ angiogram CUS Compression ultrasonography CYP3A4 Cytochrome 3A4 DAMOVES D-dimer, Age, Mutation, Obesity, Varicose veins, Eight [coagulation factor VIII], Sex DASH D-dimer, Age, Sex, Hormonal therapy DVT Deep vein thrombosis ECMO Extracorporeal membrane oxygenation ELISA Enzyme-linked immunosorbent assay EMA European Medicines Agency ERS European Respiratory Society ESC European Society of Cardiology FAST H-FABP, Syncope, Tachycardia (prognostic score) FDA US Food and Drug Administration GUSTO Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly HERDOO2 Hyperpigmentation, Edema, or Redness in either leg; D-dimer level >_250 lg/L; Obesity with body mass index >_30 kg/m2; or Older age, >_65 years H-FABP Heart-type fatty acid-binding protein HIV Human immunodeficiency virus HR Hazard ratio INR International normalized ratio IU International units i.v Intravenous IVC Inferior vena cava LA Left atrium LMWH Low-molecular weight heparin(s) LV Left ventricle/ventricular MRA Magnetic resonance angiography NCT National clinical trial NOAC(s) Non-vitamin K antagonist oral anticoagulant(s) NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OBRI Outpatient Bleeding Risk Index o.d Omni die (once a day) OR Odds ratio PAH Pulmonary arterial hypertension PAP Pulmonary artery pressure PE Pulmonary embolism PEA Pulmonary endarterectomy PEITHO Pulmonary Embolism Thrombolysis trial PERC Pulmonary Embolism Rule-out Criteria PERT Pulmonary Embolism Response Team PESI Pulmonary Embolism Severity Index Downloaded from academic.oup.com/eurheartj/article/41/4/543/5556136 by guest on 07 October 2026